跳至主要内容

Preclinical Drug Safety Ealuation and Drug Safety Testing

 The preclinical services that Medicilon offers focus on preclinical pharmacokinetic and drug safety assessment (evaluation) for foreign and domestic clients.

Drug Safety Ealuation

 

 

Preclinical Drug Safety Testing : In vitro and in vivo testing to determine if the drug is safe enough for human testing.

OUR SERVICES:

Preclinical Safety Testing Requirements

  • Selection of the relevant animal species;

  • Age;

  • Physiological state;

  • Dose, route of administration, and treatment regimen; and Stability of the test material under the conditions of use.

Platform

  • The technical service platform of evaluation of biotech drug safety on non-human primate

  • The technical service platform of experiment on non-human primate

  • The technical service platform of drug discovery and screening based on protein crystallography

  • The technical service platform of evaluation of isotope labeling drug metabolism

The Projects

More than 30 packages of non-clinical drug safety evaluation and about 800 single toxicity studies have been completed since 2012. The tested articles include small molecular drugs, biotech drugs, vaccine (monovalent and multivalent ) and traditional Chinese medicine and natural drugs.

New Drug Application

Since 2012, 15 non-clinical safety evaluation packages and more than 60 single toxicity study data generated from MPR were used by the clients in IND application to CFDA, US FDA and Australia TGA separately.

New medicines or chemicals which may affect the health of humans are required by law to be tested on animals. These safety tests, which provide crucial information for planning human trials, represent a very small proportion of the development process for a new medicine. While animal tests cannot predict all of the reactions a human may have to a given substance, broader questions about effects on the heart, liver, lungs or skin are answered through animal studies so that its relative toxicity is known. Acute toxicity tests, where a single, high dose of a substance is given to animals, are performed early on in development. The results are used to design studies which examine the compound in more detail.

Safety testing begins early in the exploratory development of a potential drug, with acute toxicity tests. These are usually carried out on a rodent species, and a non-rodent mammalian species, as this gives the minimum data necessary for making comparisons between effects on different species.
Drug safety testing is a complicated process that involves many different steps to ensure the highest level of safety.

PRECLINICAL RESEARCH

The first step in developing and testing a new drug is preclinical research. Initially, scientists consult the vast amount of published information and databases to obtain as much background information as possible. If necessary, they perform studies to determine which germ, virus, chemical, or other factor causes a disease. Then the mechanisms of the disease are studied and new drugs are developed and evaluated for effectiveness and side effects using cell culture and whole animal models. Even though scientists minimize the number of animals used by testing drugs in cell culture whenever possible, it is still important to test drugs in animals.

PRECLINICAL SAFETY ASSESSMENT TESTING

Once a drug is shown to be effective in animals and to have a low incidence of side effects, it will be proceeded to safety assessment testing. These tests are conducted to evaluate drug safety in two different animal species, with animals receiving high doses of the new drug for 30 or 90 days. Animals are carefully monitored for side effects. After the study period, pathologists examine their organs for signs of drug toxicity. This drug safety testing in animals is carried out under guidelines mandated by law through the FDA. It is the last safety testing performed before the drug is given to people for clinical testing.

Contact us

Email : marketing@medicilon.com

Tel : +86 021 5859 1500

Tips : Above is part of preclinical drug testing,Drug Safety Ealuation. You can also CONTACT US with any question or enquiry you may have. We will be happy to discuss your needs in detail and design an appropriate plan of action.

评论

此博客中的热门博文

What is preclinical testing?

In the process of  preclinical testing  of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a  preclinical research  phase followed, before which, as described above, the potential toxicity of the compou

Inventory of the three major in vitro pharmacokinetic research methods

  The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in  Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati